MedTrace Logo

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

NCT06183489 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-10-18

No results posted yet for this study

Summary

This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.

Conditions

  • Smoldering Multiple Myeloma

Interventions

DRUG

Elranatamab

Elranatamab will be administered via a subcutaneous injection (SC)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Stichting European Myeloma Network

    lead NETWORK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-14
Primary Completion
2027-07-31
Completion
2031-07-31
FDA Drug
Yes

Countries

  • Finland
  • France
  • Greece
  • Italy
  • Netherlands
  • Norway

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06183489 on ClinicalTrials.gov